Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 11-Oct-23 10:08 AM View:  | Sebree Terri B President | Zynerba Pharmaceuticals, Inc. (ZYNE) | 10-Oct-23 | Disposition (change in control) | 766,241 | -- | -- | (100%) 766.24K to 0 | |
| 11-Oct-23 10:03 AM View: | Cooper Warren D Director | Zynerba Pharmaceuticals, Inc. (ZYNE) | 10-Oct-23 | Disposition (change in control) | 75,778 | -- | -- | (100%) 75.78K to 0 | |
| 11-Oct-23 9:58 AM View: | Butler John P. Director | Zynerba Pharmaceuticals, Inc. (ZYNE) | 10-Oct-23 | Disposition (change in control) | 80,765 | -- | -- | (100%) 80.77K to 0 | |
| 11-Oct-23 9:58 AM View: | Moch Kenneth I Director | Zynerba Pharmaceuticals, Inc. (ZYNE) | 10-Oct-23 | Disposition (change in control) | 75,778 | -- | -- | (100%) 75.78K to 0 | |
| 11-Oct-23 9:52 AM View: | Anido Armando Chairman & Chief Exec. Officer Director | Zynerba Pharmaceuticals, Inc. (ZYNE) | 10-Oct-23 | Grant | 240,000 | -- | -- | 25% 976.61K to 1.22M | |
| 11-Oct-23 9:52 AM View: | Anido Armando Chairman & Chief Exec. Officer Director | Zynerba Pharmaceuticals, Inc. (ZYNE) | 10-Oct-23 | Disposition (change in control) | 39,892 | -- | -- | (100%) 39.89K to 0 | |
| 11-Oct-23 10:12 AM View: | Fickenscher James E Chief Financial Officer | Zynerba Pharmaceuticals, Inc. (ZYNE) | 10-Oct-23 | Grant | 170,000 | -- | -- | 45% 378.09K to 548.09K | |
| 11-Oct-23 10:08 AM View: | Sebree Terri B President | Zynerba Pharmaceuticals, Inc. (ZYNE) | 10-Oct-23 | Grant | 170,000 | -- | -- | 29% 596.24K to 766.24K | |
| 11-Oct-23 10:02 AM View: | Parker Albert P Chief Legal Officer | Zynerba Pharmaceuticals, Inc. (ZYNE) | 10-Oct-23 | Grant | 85,000 | -- | -- | 37% 227.02K to 312.02K | |
| 11-Oct-23 10:17 AM View: | Jones Kenneth T See Remarks | Zynerba Pharmaceuticals, Inc. (ZYNE) | 10-Oct-23 | Disposition (change in control) | 115,520 | -- | -- | (100%) 115.52K to 0 | |
| 11-Oct-23 10:05 AM View: | Rosenberger Brian VP, Commercial & Business Dev. | Zynerba Pharmaceuticals, Inc. (ZYNE) | 10-Oct-23 | Disposition (change in control) | 369,559 | -- | -- | (100%) 369.56K to 0 | |
| 11-Oct-23 10:02 AM View: | Parker Albert P Chief Legal Officer | Zynerba Pharmaceuticals, Inc. (ZYNE) | 10-Oct-23 | Disposition (change in control) | 312,018 | -- | -- | (100%) 312.02K to 0 | |
| 11-Oct-23 10:12 AM View: | Stephenson Pamela Director | Zynerba Pharmaceuticals, Inc. (ZYNE) | 10-Oct-23 | Disposition (change in control) | 75,778 | -- | -- | (100%) 75.78K to 0 | |
| 11-Oct-23 9:52 AM View: | Anido Armando Chairman & Chief Exec. Officer Director | Zynerba Pharmaceuticals, Inc. (ZYNE) | 10-Oct-23 | Disposition (change in control) | 1,176,720 | -- | -- | (97%) 1.22M to 39.89K | |
| 11-Oct-23 10:17 AM View: | Jones Kenneth T See Remarks | Zynerba Pharmaceuticals, Inc. (ZYNE) | 10-Oct-23 | Grant | 30,000 | -- | -- | 35% 85.52K to 115.52K | |
| 11-Oct-23 9:52 AM View: | Kisner Daniel L Director | Zynerba Pharmaceuticals, Inc. (ZYNE) | 10-Oct-23 | Disposition (change in control) | 75,778 | -- | -- | (100%) 75.78K to 0 | |
| 11-Oct-23 10:12 AM View: | Fickenscher James E Chief Financial Officer | Zynerba Pharmaceuticals, Inc. (ZYNE) | 10-Oct-23 | Disposition (change in control) | 548,087 | -- | -- | (100%) 548.09K to 0 | |
| 11-Oct-23 10:05 AM View: | Rosenberger Brian VP, Commercial & Business Dev. | Zynerba Pharmaceuticals, Inc. (ZYNE) | 10-Oct-23 | Grant | 120,000 | -- | -- | 48% 249.56K to 369.56K | |
| 11-Oct-23 10:07 AM View: | Federici William J Director | Zynerba Pharmaceuticals, Inc. (ZYNE) | 10-Oct-23 | Disposition (change in control) | 75,778 | -- | -- | (100%) 75.78K to 0 | |
| 14-Sep-23 4:13 PM View: | Jones Kenneth T See Remarks | Zynerba Pharmaceuticals, Inc. (ZYNE) | 13-Sep-23 | Sale | 2,505 | $1.33 | $3,320.88 | (3%) 88.03K to 85.52K | |
| 14-Sep-23 4:14 PM View: | Rosenberger Brian VP, Commercial & Business Dev. | Zynerba Pharmaceuticals, Inc. (ZYNE) | 13-Sep-23 | Sale | 6,411 | $1.33 | $8,499.06 | (3%) 255.97K to 249.56K | |
| 14-Sep-23 4:13 PM View: | Anido Armando Chairman & Chief Exec. Officer Director | Zynerba Pharmaceuticals, Inc. (ZYNE) | 13-Sep-23 | Sale | 17,830 | $1.33 | $23,637.20 | (2%) 967.85K to 950.02K | |
| 14-Sep-23 4:13 PM View: | Fickenscher James E Chief Financial Officer | Zynerba Pharmaceuticals, Inc. (ZYNE) | 13-Sep-23 | Sale | 8,998 | $1.33 | $11,928.60 | (2%) 387.08K to 378.09K | |
| 14-Sep-23 4:14 PM View: | Sebree Terri B President | Zynerba Pharmaceuticals, Inc. (ZYNE) | 13-Sep-23 | Sale | 12,401 | $1.33 | $16,440.00 | (2%) 608.64K to 596.24K | |
| 14-Sep-23 4:13 PM View: | Jones Kenneth T See Remarks | Zynerba Pharmaceuticals, Inc. (ZYNE) | 12-Sep-23 | Grant | 9,000 | -- | -- | 11% 79.03K to 88.03K | |
| 14-Sep-23 4:14 PM View: | Rosenberger Brian VP, Commercial & Business Dev. | Zynerba Pharmaceuticals, Inc. (ZYNE) | 12-Sep-23 | Grant | 22,200 | -- | -- | 9% 233.77K to 255.97K | |
| 14-Sep-23 4:13 PM View: | Anido Armando Chairman & Chief Exec. Officer Director | Zynerba Pharmaceuticals, Inc. (ZYNE) | 12-Sep-23 | Grant | 64,747 | -- | -- | 7% 903.1K to 967.85K | |
| 14-Sep-23 4:13 PM View: | Fickenscher James E Chief Financial Officer | Zynerba Pharmaceuticals, Inc. (ZYNE) | 12-Sep-23 | Grant | 31,200 | -- | -- | 9% 355.88K to 387.08K | |
| 14-Sep-23 4:14 PM View: | Sebree Terri B President | Zynerba Pharmaceuticals, Inc. (ZYNE) | 12-Sep-23 | Grant | 45,000 | -- | -- | 8% 563.64K to 608.64K | |
| 15-Jun-23 4:30 PM View: | Stephenson Pamela Director | Zynerba Pharmaceuticals, Inc. (ZYNE) | 14-Jun-23 | Sale | 115 | $0.35 | $40.03 | (< 1%) 75.89K to 75.78K | |
| 15-Jun-23 4:29 PM View: | Kisner Daniel L Director | Zynerba Pharmaceuticals, Inc. (ZYNE) | 14-Jun-23 | Sale | 115 | $0.35 | $40.03 | (< 1%) 75.89K to 75.78K | |
| 15-Jun-23 4:29 PM View: | Federici William J Director | Zynerba Pharmaceuticals, Inc. (ZYNE) | 14-Jun-23 | Sale | 115 | $0.35 | $40.03 | (< 1%) 75.89K to 75.78K | |
| 15-Jun-23 4:28 PM View: | Cooper Warren D Director | Zynerba Pharmaceuticals, Inc. (ZYNE) | 14-Jun-23 | Sale | 115 | $0.35 | $40.03 | (< 1%) 75.89K to 75.78K | |
| 15-Jun-23 4:28 PM View: | Butler John P. Director | Zynerba Pharmaceuticals, Inc. (ZYNE) | 14-Jun-23 | Sale | 115 | $0.35 | $40.03 | (< 1%) 80.88K to 80.77K | |
| 15-Jun-23 4:30 PM View: | Moch Kenneth I Director | Zynerba Pharmaceuticals, Inc. (ZYNE) | 14-Jun-23 | Sale | 115 | $0.35 | $40.03 | (< 1%) 75.89K to 75.78K | |
| 15-Jun-23 4:30 PM View: | Stephenson Pamela Director | Zynerba Pharmaceuticals, Inc. (ZYNE) | 13-Jun-23 | Grant | 47,824 | -- | -- | 170% 28.07K to 75.89K | |
| 15-Jun-23 4:29 PM View: | Kisner Daniel L Director | Zynerba Pharmaceuticals, Inc. (ZYNE) | 13-Jun-23 | Grant | 47,824 | -- | -- | 170% 28.07K to 75.89K | |
| 15-Jun-23 4:29 PM View: | Federici William J Director | Zynerba Pharmaceuticals, Inc. (ZYNE) | 13-Jun-23 | Grant | 47,824 | -- | -- | 170% 28.07K to 75.89K | |
| 15-Jun-23 4:28 PM View: | Cooper Warren D Director | Zynerba Pharmaceuticals, Inc. (ZYNE) | 13-Jun-23 | Grant | 47,824 | -- | -- | 170% 28.07K to 75.89K | |
| 15-Jun-23 4:28 PM View: | Butler John P. Director | Zynerba Pharmaceuticals, Inc. (ZYNE) | 13-Jun-23 | Grant | 47,824 | -- | -- | 145% 33.06K to 80.88K | |
| 15-Jun-23 4:30 PM View: | Moch Kenneth I Director | Zynerba Pharmaceuticals, Inc. (ZYNE) | 13-Jun-23 | Grant | 47,824 | -- | -- | 170% 28.07K to 75.89K | |
| 17-Feb-23 4:21 PM View: | Parker Albert P Chief Legal Officer | Zynerba Pharmaceuticals, Inc. (ZYNE) | 15-Feb-23 | Sale | 3,173 | $0.54 | $1,719.13 | (1%) 230.19K to 227.02K | |
| 09-Feb-23 5:10 PM View: | Anido Armando Chairman & Chief Exec. Officer Director | Zynerba Pharmaceuticals, Inc. (ZYNE) | 08-Feb-23 | Payment of Exercise | 12,547 | $0.60 | $7,484.29 | (1%) 915.65K to 903.1K | |
| 09-Feb-23 5:20 PM View: | Rosenberger Brian VP, Commercial & Business Dev. | Zynerba Pharmaceuticals, Inc. (ZYNE) | 08-Feb-23 | Payment of Exercise | 5,145 | $0.60 | $3,068.99 | (2%) 238.91K to 233.77K | |
| 09-Feb-23 5:09 PM View: | Parker Albert P Chief Legal Officer | Zynerba Pharmaceuticals, Inc. (ZYNE) | 08-Feb-23 | Payment of Exercise | 5,463 | $0.60 | $3,258.68 | (2%) 235.65K to 230.19K | |
| 09-Feb-23 5:11 PM View: | Fickenscher James E Chief Financial Officer | Zynerba Pharmaceuticals, Inc. (ZYNE) | 08-Feb-23 | Payment of Exercise | 6,544 | $0.60 | $3,903.50 | (2%) 362.43K to 355.88K | |
| 09-Feb-23 5:11 PM View: | Sebree Terri B President | Zynerba Pharmaceuticals, Inc. (ZYNE) | 08-Feb-23 | Payment of Exercise | 9,973 | $0.60 | $5,948.89 | (2%) 573.62K to 563.64K | |
| 09-Feb-23 5:11 PM View: | Fickenscher James E Chief Financial Officer | Zynerba Pharmaceuticals, Inc. (ZYNE) | 07-Feb-23 | Grant | 22,547 | -- | -- | 7% 339.88K to 362.43K | |
| 09-Feb-23 5:11 PM View: | Sebree Terri B President | Zynerba Pharmaceuticals, Inc. (ZYNE) | 07-Feb-23 | Grant | 36,044 | -- | -- | 7% 537.57K to 573.62K | |
| 09-Feb-23 5:10 PM View: | Anido Armando Chairman & Chief Exec. Officer Director | Zynerba Pharmaceuticals, Inc. (ZYNE) | 07-Feb-23 | Grant | 45,406 | -- | -- | 5% 870.24K to 915.65K |
